RUNX3 Suppresses Gastric Epithelial Cell Growth by Inducing p21 Expression in Cooperation with Transforming Growth Factor (cid:2) -Activated SMAD

RUNX3 has been suggested to be a tumor suppressor of gastric cancer. The gastric mucosa of the Runx3 -null mouse develops hyperplasia due to enhanced proliferation and suppressed apoptosis accompanied by a decreased sensitivity to transforming growth factor (cid:1) 1 (TGF- (cid:1) 1). It is known that TGF- (cid:1) 1 induces cell growth arrest by activating CDKN1A ( p21 WAF1 / Cip1 ), which encodes a cyclin-dependent kinase inhibitor, and this signaling cascade is considered to be a tumor suppressor pathway. However, the lineage-specific transcription factor that cooperates with SMADs to induce p21 expression is not known. Here we show that RUNX3 is required for the TGF- (cid:1) -dependent induction of p21 expression in stomach epithelial cells. Overexpression of RUNX3 potentiates TGF- (cid:1) -dependent endogenous p21 induction. In cooperation with SMADs, RUNX3 synergistically activates the p21 promoter. In contrast, RUNX3 - R122C , a mutation identified in a gastric cancer patient, abolished the ability to activate the p21 promoter or cooperate with SMADs. Furthermore, areas in mouse and human gastric epithelium where RUNX3 is expressed coincided with those where p21 is expressed. Our results suggest that at least part of the tumor suppressor activity of RUNX3 is associated with its ability to induce p21 expression.

[1]  C. Compton,et al.  Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers , 2004, International journal of cancer.

[2]  S. Anderson,et al.  Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation , 2004, Cell.

[3]  Kazuhiro Yoshida,et al.  Frequent Loss of RUNX3 Expression by Promoter Hypermethylation in Gastric Carcinoma , 2004, Pathobiology.

[4]  Hyeon Joo Lee,et al.  Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma , 2004, Laboratory Investigation.

[5]  W. Xiao,et al.  Hemizygous deletion and hypermethylation of RUNX3 gene in hepatocellular carcinoma. , 2004, World journal of gastroenterology.

[6]  Hyeon Joo Lee,et al.  Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia , 2004, The Journal of pathology.

[7]  Hoguen Kim,et al.  Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. , 2004, Biochemical and biophysical research communications.

[8]  T. Motoyama,et al.  Promoter hypermethylation of tumor suppressor and tumor‐related genes in non‐small cell lung cancers , 2003, Cancer science.

[9]  Yoram Groner,et al.  Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  C. Sakakura,et al.  Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines , 2003, Oncogene.

[11]  M. Tatematsu,et al.  Inhibition of growth of mouse gastric cancer cells by Runx3, a novel tumor suppressor , 2002, Oncogene.

[12]  D. Littman,et al.  Differential Requirements for Runx Proteins in CD4 Repression and Epigenetic Silencing during T Lymphocyte Development , 2002, Cell.

[13]  S. K. Zaidi,et al.  Runx2 (Cbfa1, AML-3) Interacts with Histone Deacetylase 6 and Represses the p21CIP1/WAF1 Promoter , 2002, Molecular and Cellular Biology.

[14]  S. Itohara,et al.  Runx3 controls the axonal projection of proprioceptive dorsal root ganglion neurons , 2002, Nature Neuroscience.

[15]  J. Gergen,et al.  Distinct in vivo requirements for establishment versus maintenance of transcriptional repression , 2002, Nature Genetics.

[16]  A. Lev-Tov,et al.  The Runx3 transcription factor regulates development and survival of TrkC dorsal root ganglia neurons , 2002, The EMBO journal.

[17]  A. Balmain.  Cancer: New-age tumour suppressors , 2002, Nature.

[18]  S. Itohara,et al.  Causal Relationship between the Loss of RUNX3 Expression and Gastric Cancer , 2002, Cell.

[19]  H. Moses,et al.  Regulation of Plasminogen Activator Inhibitor-1 Expression by Transforming Growth Factor-β-induced Physical and Functional Interactions between Smads and Sp1* , 2000, The Journal of Biological Chemistry.

[20]  J. Massagué,et al.  TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders , 2000, Cell.

[21]  A. Moustakas,et al.  Role of Smad Proteins and Transcription Factor Sp1 in p21Waf1/Cip1 Regulation by Transforming Growth Factor-β* , 2000, The Journal of Biological Chemistry.

[22]  E. Seto,et al.  A Mechanism of Repression by Acute Myeloid Leukemia-1, the Target of Multiple Chromosomal Translocations in Acute Leukemia* , 2000, The Journal of Biological Chemistry.

[23]  K. Miyazono,et al.  Interaction and Functional Cooperation of PEBP2/CBF with Smads , 1999, The Journal of Biological Chemistry.

[24]  A. Moustakas,et al.  Regulation of the human p21/WAF1/Cip1 promoter in hepatic cells by functional interactions between Sp1 and Smad family members. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Suzuki,et al.  Activation of the human transglutaminase 1 promoter in transgenic mice: terminal differentiation-specific expression of the TGM1-lacZ transgene in keratinized stratified squamous epithelia. , 1997, Human molecular genetics.

[26]  A T Look,et al.  Oncogenic transcription factors in the human acute leukemias. , 1997, Science.

[27]  Y. Houvras,et al.  Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl , 1997, Nature.

[28]  A. Baldini,et al.  Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia , 1997, Nature Genetics.

[29]  S. Mundlos,et al.  Cbfa1, a Candidate Gene for Cleidocranial Dysplasia Syndrome, Is Essential for Osteoblast Differentiation and Bone Development , 1997, Cell.

[30]  M. Owen,et al.  Mutations Involving the Transcription Factor CBFA1 Cause Cleidocranial Dysplasia , 1997, Cell.

[31]  M. Nikolic,et al.  Sensitivity to transforming growth factor beta 1-induced growth arrest is common in human squamous cell carcinoma cell lines: c-MYC down-regulation and p21waf1 induction are important early events. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[32]  J. Downing,et al.  AML1, the Target of Multiple Chromosomal Translocations in Human Leukemia, Is Essential for Normal Fetal Liver Hematopoiesis , 1996, Cell.

[33]  James M. Roberts,et al.  Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.

[34]  James M. Roberts,et al.  Cloning of p27 Kip1 , a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals , 1994, Cell.

[35]  David Beach,et al.  p21 is a universal inhibitor of cyclin kinases , 1993, Nature.

[36]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[37]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[38]  J. Nevins,et al.  Expression of transcription factor E2F1 induces quiescent cells to enter S phase , 1993, Nature.

[39]  Joseph R. Nevins,et al.  The E2F transcription factor is a cellular target for the RB protein , 1991, Cell.

[40]  S. Nagata,et al.  pEF-BOS, a powerful mammalian expression vector. , 1990, Nucleic acids research.

[41]  Chang-Woo Song,et al.  cDNA microarray gene expression profiling of hydroxyurea, paclitaxel, and p‐anisidine, genotoxic compounds with differing tumorigenicity results , 2003, Environmental and molecular mutagenesis.

[42]  A. Balmain,et al.  TGF-beta signaling in tumor suppression and cancer progression. , 2001, Nature genetics.

[43]  Kim,et al.  Genetic changes in the transforming growth factor f8 (TGF-fi) type II receptor gene in human gastric cancer cells: Correlation with sensitivity to growth inhibition by TGF-, , 2022 .